Hirsch FR. An Update on the BLUEPRINT and Related Projects. 18th World Conference on Lung Cancer (WCLC) 2017, abstract MS 18.02.
Omalizumab vermindert jeuk gerelateerd aan checkpointremmers en anti-HER2-therapieën
jun 2021 | Borstkanker, Immuuntherapie, Longoncologie, Uro-oncologie